SUSAN BLANEY to Humans
This is a "connection" page, showing publications SUSAN BLANEY has written about Humans.
Connection Strength
0.943
-
COVID-19 outcomes in a large pediatric hematology-oncology center in Houston, Texas. Pediatr Hematol Oncol. 2021 Nov; 38(8):695-706.
Score: 0.021
-
A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. Pediatr Blood Cancer. 2020 06; 67(6):e28283.
Score: 0.019
-
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatr Blood Cancer. 2020 02; 67(2):e28073.
Score: 0.019
-
Editorial: Recent advances in pediatric oncology. Curr Opin Pediatr. 2019 02; 31(1):1-2.
Score: 0.018
-
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer. 2018 08; 65(8):e27066.
Score: 0.017
-
Recent advances in pediatric oncology. Curr Opin Pediatr. 2018 02; 30(1):1-2.
Score: 0.016
-
A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer. 2018 Feb; 65(2).
Score: 0.016
-
Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15; 23(20):6062-6069.
Score: 0.016
-
A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). Br J Haematol. 2017 05; 177(3):467-474.
Score: 0.015
-
50 Years Ago in The Journal of Pediatrics: Diencephalic Syndromes of Infancy: Report of 3 Children with Emaciation Syndrome and Disproportionately Large Hands and Feet. J Pediatr. 2017 03; 182:113.
Score: 0.015
-
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 Oct; 62(10):1717-24.
Score: 0.014
-
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Sep; 62(9):1562-6.
Score: 0.014
-
A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. Pediatr Blood Cancer. 2015 May; 62(5):751-8.
Score: 0.013
-
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2015 Apr 01; 21(7):1558-65.
Score: 0.013
-
Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Mar; 62(3):440-4.
Score: 0.013
-
A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2015 Feb; 17(2):303-11.
Score: 0.013
-
Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatr Blood Cancer. 2015 May; 62(5):743-50.
Score: 0.013
-
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. Neuro Oncol. 2014 Dec; 16(12):1661-8.
Score: 0.013
-
A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res. 2013 Dec 01; 19(23):6578-84.
Score: 0.012
-
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Mar; 61(3):452-6.
Score: 0.012
-
Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol. 2013 Aug 20; 31(24):3034-43.
Score: 0.012
-
Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. Neuro Oncol. 2013 Jun; 15(6):759-66.
Score: 0.012
-
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep; 60(9):1452-7.
Score: 0.012
-
A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study. Pediatr Blood Cancer. 2013 Apr; 60(4):627-32.
Score: 0.011
-
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012 Nov 01; 18(21):6011-22.
Score: 0.011
-
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013 Mar; 60(3):390-5.
Score: 0.011
-
Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). J Neurooncol. 2012 Sep; 109(3):565-71.
Score: 0.011
-
Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2013 Feb; 60(2):237-41.
Score: 0.011
-
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jan 20; 30(3):256-62.
Score: 0.011
-
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol. 2012 Apr; 69(4):1021-7.
Score: 0.011
-
A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer. 2012 Mar; 48(4):579-85.
Score: 0.011
-
Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatr Blood Cancer. 2012 Mar; 58(3):362-5.
Score: 0.010
-
A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study. Neuro Oncol. 2011 Aug; 13(8):910-5.
Score: 0.010
-
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 01; 17(15):5113-22.
Score: 0.010
-
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol. 2011 Jan 20; 29(3):316-23.
Score: 0.010
-
Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res. 2011 Feb 01; 17(3):589-97.
Score: 0.010
-
Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2010 Jul 15; 55(1):119-22.
Score: 0.010
-
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study. Cancer. 2009 Apr 15; 115(8):1765-75.
Score: 0.009
-
Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. Pediatr Blood Cancer. 2008 Oct; 51(4):504-8.
Score: 0.009
-
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007 Oct 10; 25(29):4622-7.
Score: 0.008
-
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol. 2008 Jul; 62(2):355-61.
Score: 0.008
-
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 01; 13(5):1516-22.
Score: 0.008
-
Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors. Pediatr Blood Cancer. 2006 Aug; 47(2):163-8.
Score: 0.007
-
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol. 2006 Aug 01; 24(22):3678-85.
Score: 0.007
-
New agents for intrathecal administration. Cancer Invest. 2006 Aug-Sep; 24(5):528-34.
Score: 0.007
-
A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer. 2006 Jan; 46(1):50-5.
Score: 0.007
-
New approaches to drug development in pediatric oncology. Cancer J. 2005 Jul-Aug; 11(4):324-30.
Score: 0.007
-
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005 Mar 01; 23(7):1555-63.
Score: 0.007
-
Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005 Jan 20; 23(3):525-31.
Score: 0.007
-
Leptomeningeal cancer in the pediatric patient. Cancer Treat Res. 2005; 125:87-106.
Score: 0.007
-
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol. 2004 Dec 01; 22(23):4804-9.
Score: 0.007
-
Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004 Oct 01; 22(19):3916-21.
Score: 0.006
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
Score: 0.006
-
Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. Cancer Chemother Pharmacol. 2003 Nov; 52(5):417-23.
Score: 0.006
-
Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003 Jan 01; 21(1):143-7.
Score: 0.006
-
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. Neuro Oncol. 2022 04 01; 24(4):655-664.
Score: 0.005
-
Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol. 2002 Feb; 24(2):130-3.
Score: 0.005
-
Meropenem pharmacokinetics in children and adolescents receiving hemodialysis. Pediatr Nephrol. 2001 Dec; 16(12):1015-8.
Score: 0.005
-
Treatment controversies in medulloblastoma. Curr Opin Oncol. 2001 May; 13(3):154-9.
Score: 0.005
-
Intrathecal chemotherapy. Crit Rev Oncol Hematol. 2001 Mar; 37(3):227-36.
Score: 0.005
-
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 07 01; 27(13):3543-3548.
Score: 0.005
-
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res. 2001 Jan; 7(1):32-7.
Score: 0.005
-
The development of camptothecin analogs in childhood cancers. Oncologist. 2001; 6(6):506-16.
Score: 0.005
-
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). Cancer Chemother Pharmacol. 2020 12; 86(6):829-840.
Score: 0.005
-
Clinical pharmacology of encapsulated sustained-release cytarabine. Ann Pharmacother. 2000 Oct; 34(10):1173-8.
Score: 0.005
-
Neoplastic meningitis: diagnosis and treatment considerations. Med Oncol. 2000 Aug; 17(3):151-62.
Score: 0.005
-
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2020 06 09; 22(6):875-885.
Score: 0.005
-
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clin Cancer Res. 2019 06 01; 25(11):3229-3238.
Score: 0.004
-
Current Activities of the Coalition of Cancer Cooperative Groups. J Natl Cancer Inst. 2019 01 01; 111(1):11-18.
Score: 0.004
-
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018 09; 19(9):1229-1238.
Score: 0.004
-
New cytotoxic drugs for intrathecal administration. J Neurooncol. 1998 Jun-Jul; 38(2-3):219-23.
Score: 0.004
-
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 08; 65(8):e27077.
Score: 0.004
-
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
Score: 0.004
-
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 03; 65(3).
Score: 0.004
-
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol. 2017 Oct 01; 35(28):3215-3221.
Score: 0.004
-
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatr Blood Cancer. 2017 Nov; 64(11).
Score: 0.004
-
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997 Apr; 15(4):1538-43.
Score: 0.004
-
First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium. Cancer Chemother Pharmacol. 2017 Jan; 79(1):181-187.
Score: 0.004
-
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
Score: 0.004
-
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. J Clin Oncol. 2016 09 01; 34(25):3031-8.
Score: 0.004
-
Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. Cancer Med. 2016 07; 5(7):1416-24.
Score: 0.004
-
Central nervous system leukemia. Curr Opin Oncol. 1996 Jan; 8(1):13-9.
Score: 0.004
-
Pharmacologic strategies for the treatment of meningeal malignancy. Invest New Drugs. 1996; 14(1):69-85.
Score: 0.004
-
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug; 31(8):1283-9.
Score: 0.003
-
Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr Blood Cancer. 2015 Jan; 62(1):45-51.
Score: 0.003
-
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014 Sep; 61(9):1598-602.
Score: 0.003
-
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2013 Sep; 114(2):173-9.
Score: 0.003
-
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May; 14(6):472-80.
Score: 0.003
-
Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts. Biochem Pharmacol. 1993 Apr 06; 45(7):1493-501.
Score: 0.003
-
Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993 Mar 01; 53(5):1032-6.
Score: 0.003
-
Doxorubicin: role in the treatment of osteosarcoma. Cancer Treat Res. 1993; 62:55-73.
Score: 0.003
-
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin Cancer Res. 2012 Nov 01; 18(21):6058-64.
Score: 0.003
-
A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report. Clin Cancer Res. 2012 Sep 15; 18(18):5081-9.
Score: 0.003
-
Modulation of the cytotoxic effect of cyclopentenylcytosine by its primary metabolite, cyclopentenyluridine. Cancer Res. 1992 Jun 15; 52(12):3503-5.
Score: 0.003
-
Vascular-targeted photothermal therapy of an orthotopic murine glioma model. Nanomedicine (Lond). 2012 Aug; 7(8):1133-48.
Score: 0.003
-
Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study. Arch Pathol Lab Med. 2011 Aug; 135(8):984-93.
Score: 0.003
-
Current pharmacological treatment approaches to central nervous system leukaemia. Drugs. 1991 May; 41(5):702-16.
Score: 0.003
-
Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Williston Park). 1991 May; 5(5):107-16; discussion 123, 127.
Score: 0.003
-
Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study. Proteomics. 2011 Mar; 11(5):935-43.
Score: 0.003
-
Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol. 2011 Mar 01; 29(7):839-44.
Score: 0.003
-
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol. 2011 Jan 20; 29(3):324-9.
Score: 0.002
-
Nanoshell-mediated photothermal therapy improves survival in a murine glioma model. J Neurooncol. 2011 Aug; 104(1):55-63.
Score: 0.002
-
A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol. 2011 Jan; 13(1):14-27.
Score: 0.002
-
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011 Aug; 57(2):275-82.
Score: 0.002
-
Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Oct; 55(4):629-38.
Score: 0.002
-
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Feb; 56(2):226-33.
Score: 0.002
-
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Sep; 55(3):440-5.
Score: 0.002
-
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010 Sep 20; 28(27):4221-7.
Score: 0.002
-
A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Dec 15; 55(7):1323-8.
Score: 0.002
-
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010 Dec; 46(18):3287-93.
Score: 0.002
-
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol. 2010 Aug 01; 28(22):3623-9.
Score: 0.002
-
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr; 54(4):538-45.
Score: 0.002
-
A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol. 2010 Jun; 12(6):580-94.
Score: 0.002
-
Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res. 2010 Jan 15; 16(2):750-4.
Score: 0.002
-
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009 Aug; 8(8):2232-42.
Score: 0.002
-
Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010 Feb; 65(3):419-25.
Score: 0.002
-
Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar; 52(3):346-50.
Score: 0.002
-
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer. 2009 Feb; 52(2):169-76.
Score: 0.002
-
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol. 2008 Oct 20; 26(30):4921-7.
Score: 0.002
-
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol. 2008 Oct; 10(5):752-8.
Score: 0.002
-
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol. 2008 Aug 01; 26(22):3756-62.
Score: 0.002
-
Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist. 2008 Jun; 13(6):679-89.
Score: 0.002
-
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Neuro Oncol. 2008 Aug; 10(4):569-76.
Score: 0.002
-
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol. 2008 Jun; 10(3):341-7.
Score: 0.002
-
Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells. 2008 Jun; 26(6):1414-24.
Score: 0.002
-
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. 2009 Jan; 63(2):229-38.
Score: 0.002
-
Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Pediatr Blood Cancer. 2008 Apr; 50(4):757-60.
Score: 0.002
-
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar; 50(3):577-80.
Score: 0.002
-
Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar; 50(3):549-53.
Score: 0.002
-
Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer Chemother Pharmacol. 2008 Nov; 62(6):1027-37.
Score: 0.002
-
Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res. 2008 Feb 15; 14(4):1124-30.
Score: 0.002
-
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Feb; 50(2):254-8.
Score: 0.002
-
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405.
Score: 0.002
-
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 01; 25(31):4922-8.
Score: 0.002
-
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood. 2008 Jan 15; 111(2):566-73.
Score: 0.002
-
Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J Neurooncol. 2008 Jan; 86(2):165-72.
Score: 0.002
-
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatr Blood Cancer. 2007 Sep; 49(3):352-7.
Score: 0.002
-
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007 Jul 20; 25(21):3137-43.
Score: 0.002
-
Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol. 2007 Apr 20; 25(12):1505-11.
Score: 0.002
-
Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007 Apr 20; 25(12):1512-8.
Score: 0.002
-
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 15; 13(6):1789-93.
Score: 0.002
-
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007 Apr; 9(2):145-60.
Score: 0.002
-
Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol. 2007 Feb; 33(1):67-76.
Score: 0.002
-
Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007 May; 59(6):847-53.
Score: 0.002
-
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2006 Nov; 47(6):790-4.
Score: 0.002
-
Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer. 2006 Nov 01; 107(9):2291-7.
Score: 0.002
-
Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Clin Cancer Res. 2006 Aug 01; 12(15):4687-94.
Score: 0.002
-
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
Score: 0.002
-
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res. 2006 Mar 01; 12(5):1540-6.
Score: 0.002
-
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol. 2006 Jan 20; 24(3):507-16.
Score: 0.002
-
Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther. 2005 Dec; 4(12):1912-22.
Score: 0.002
-
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006 Jul; 58(1):13-23.
Score: 0.002
-
Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study. Pediatr Blood Cancer. 2005 Oct 15; 45(5):644-8.
Score: 0.002
-
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2005 Sep 01; 23(25):6172-80.
Score: 0.002
-
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20; 23(15):3376-82.
Score: 0.002
-
Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005 Mar 01; 23(7):1491-9.
Score: 0.002
-
Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res. 2005 Mar 01; 11(5):1884-9.
Score: 0.002
-
A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):672-7.
Score: 0.002
-
Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005 Jan; 19(1):34-8.
Score: 0.002
-
Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res. 2005 Jan 01; 65(1):76-84.
Score: 0.002
-
Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 01; 22(21):4394-400.
Score: 0.002
-
Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines. Anticancer Drugs. 2004 Oct; 15(9):883-8.
Score: 0.002
-
Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. Clin Cancer Res. 2004 Aug 01; 10(15):5072-5.
Score: 0.002
-
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004 Nov 01; 104(9):2655-60.
Score: 0.002
-
Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study. J Clin Oncol. 2004 Apr 15; 22(8):1413-9.
Score: 0.002
-
Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Cancer Chemother Pharmacol. 2004 Jun; 53(6):482-8.
Score: 0.002
-
Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res. 2004 Feb 01; 10(3):1150-9.
Score: 0.002
-
Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003 Jul; 25(7):526-33.
Score: 0.001
-
Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003 Jul; 25(7):539-42.
Score: 0.001
-
Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin Cancer Res. 2003 Feb; 9(2):703-10.
Score: 0.001
-
Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002 Dec; 8(12):3646-57.
Score: 0.001
-
Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol. 2002 Jun-Jul; 24(5):337-42.
Score: 0.001
-
Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res. 2002 Feb; 8(2):413-8.
Score: 0.001
-
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol. 2001 Feb 01; 19(3):697-704.
Score: 0.001
-
Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 2000 Nov-Dec; 22(6):506-9.
Score: 0.001
-
Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine. J Pharmacol Exp Ther. 1999 Nov; 291(2):870-4.
Score: 0.001
-
Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1999 Nov-Dec; 21(6):494-500.
Score: 0.001
-
Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res. 1999 Apr; 5(4):733-7.
Score: 0.001
-
Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 1998 Jul; 16(7):2494-9.
Score: 0.001
-
Clear cell sarcoma of the kidney: an unusual presentation and review of the literature. J Pediatr Hematol Oncol. 1998 Mar-Apr; 20(2):165-8.
Score: 0.001
-
Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol. 1998 Jan; 16(1):181-6.
Score: 0.001
-
Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol. 1997 Nov; 15(11):3330-7.
Score: 0.001
-
A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer. 1995 Dec 15; 76(12):2557-64.
Score: 0.001
-
A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res. 1995 Sep 15; 55(18):4069-72.
Score: 0.001
-
Acute pancreatitis after ifosfamide therapy. Cancer. 1994 Sep 01; 74(5):1627-8.
Score: 0.001
-
Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis. 1992 Jan; 165(1):99-104.
Score: 0.001
-
Antiretroviral drug development and clinical pharmacology. Pediatr Infect Dis J. 1991 Nov; 10(11):849-57.
Score: 0.001